Cell Screening Device Maker DVS Takes $14.6 Million, Targets Pharma As Customers
This article was originally published in The Pink Sheet Daily
Executive Summary
Spun out of the University of Toronto, the young start-up looked to Silicon Valley and corporate pharma investors for capital.
You may also be interested in...
In Vitro Diagnostics: The Quest For Growth
This article first appeared in Medtech Insight, October 2010.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.